| BCBS Massachusetts | Overactive Bladder Medications | 2025-01-01 |
| Health Net Comm & Medi-Cal Plan | Genetic Testing for Hereditary Cancer Susceptibility | 2025-01-01 |
| HealthPartners | Filgrastim (Neupogen®, Nivestym®, Zarxio®, | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Iobenguane I-131 (Azedra) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Tarlatamab-dlle (Imdelltra) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Nogapendekin alfa inbakicept-pmln (Anktiva) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Pharmacologic Treatment of Pulmonary Arterial Hypertension | 2025-01-01 |
| BCBS Highmark Penn Medicare Advantage | Multiple Imaging in Oncology | 2025-01-01 |
| BCBS Highmark Penn Medicare Advantage | Ambulatory Electrocardiograph Monitoring | 2025-01-01 |
| BCBS Highmark Penn Medicare Advantage | Cardiac Rhythm Device Evaluation | 2025-01-01 |